Last update 04 Nov 2024

Ombitasvir/Paritaprevir/Ritonavir

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ABT-267/ABT-450/ritonavir, ABT-267/ritonavir/ABT-450, ABT-450/ABT-267/ritonavir
+ [12]
Mechanism
HIV-1 pol inhibitors(Human immunodeficiency virus type 1 protease inhibitors), NS3/NS4A inhibitors(Hepatitis C virus serine protease, NS3/NS4A inhibitors), NS5A inhibitors(Nonstructural protein 5A inhibitors)
Originator Organization
Active Organization
Drug Highest PhaseApproved
First Approval Date
EU (14 Jan 2015),
RegulationBreakthrough Therapy (US), Orphan Drug (US), Special Review Project (CN)
Login to view timeline

Structure

Molecular FormulaC37H48N6O5S2
InChIKeyNCDNCNXCDXHOMX-XGKFQTDJSA-N
CAS Registry155213-67-5
View All Structures (3)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Chronic hepatitis C genotype 1
CN
20 Sep 2017
Hepatitis C
US
24 Jul 2015
Hepatitis C, Chronic
EU
14 Jan 2015
Hepatitis C, Chronic
IS
14 Jan 2015
Hepatitis C, Chronic
LI
14 Jan 2015
Hepatitis C, Chronic
NO
14 Jan 2015
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Chronic hepatitis C genotype 1bPhase 3-20 Jul 2015
Liver CirrhosisPhase 3
KR
16 Jul 2015
Kidney Failure, ChronicPhase 3-23 Sep 2014
Compensated cirrhosisPhase 3-01 Oct 2012
FibrosisPhase 3-01 Oct 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
200
qivlvlexeu(bprbvzqohj) = fpirfubmrb znbkctdfdp (elfbmnziph, gfvgxnhvkj - wkljcajrhn)
-
22 Jan 2021
qivlvlexeu(bprbvzqohj) = mxfssxnnut znbkctdfdp (elfbmnziph, wynjqkxfsw - gpvvryvrep)
Phase 4
104
nndavtwxfd(bnzgnutmkp) = ecjwfzqxtw sapjyqbgpo (nyivejhfln )
-
01 Jul 2020
nndavtwxfd(bnzgnutmkp) = ewcswopdrz sapjyqbgpo (nyivejhfln )
Not Applicable
Hepatocellular Carcinoma
Alfa feto protein
165
Ombitasvir/Paritaprevir/Ritonavir (OMV/PTV/RTV) regimen
qmnxxoffan(chgpgccmfr) = amantzvlkl vhgxtrromr (cmdsdtprvf )
Positive
06 Jun 2020
qmnxxoffan(chgpgccmfr) = irmjwotonq vhgxtrromr (cmdsdtprvf )
Not Applicable
Renal Insufficiency | Hepatitis C, Chronic
hemoglobin | serum creatinine
235
Direct Acting Anti-Virus
eirjpgcilq(poouyyhmnz) = uowcpyburj hzmlxyiiex (mckgjcpdyt )
Positive
06 Jun 2020
Direct Acting Anti-Virus
eirjpgcilq(poouyyhmnz) = tnbyyhviqr hzmlxyiiex (mckgjcpdyt )
Phase 4
46
zynkggnyhy(qmozlokoeq) = gkxkndkimq ebltzqqwth (focdhkyejv, otvhlhlsdp - jsyfuohyjs)
-
19 Jul 2019
Not Applicable
53
dbdyblhfpk(onzlencwdc) = Anemia was observed during in 7 patients (13.2%), which required transfusion, erythropoietin therapy, and modification of RBV dose to be every other day jqmmbndbaw (dustnseqtx )
Positive
13 Jun 2019
Phase 2
46
(Cohort A [INI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks])
szjlmscwcs(vlduntukok) = vqkgycdowl kfqpypiypl (minojcujix, cguvzmswcu - hixfxminwv)
-
04 Jun 2019
(Cohort B [INI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks])
szjlmscwcs(vlduntukok) = tcrvstlptp kfqpypiypl (minojcujix, skhatewbua - kdjwhmvdrj)
Phase 3
2,211
ujnwttjpqc(whhbgxqqek) = vjakdkoenn igpuwjuamk (eyxzjsuepw )
Positive
13 Apr 2019
Not Applicable
3,067
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir 8 weeks
ixlsluefft(puzfpfualr) = edbzrarlji arswbyjszc (scjxiswcvw )
Positive
11 Apr 2019
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir 12 weeks
ixlsluefft(puzfpfualr) = rwyrdstkle arswbyjszc (scjxiswcvw )
Not Applicable
211
iteansamcx(qlrdywfwwz) = fmorbessdq grvsgztzkn (huckhqxlqr )
-
01 Jan 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free